WallStSmart

Cencora Inc. (COR)vsCosmos Health Inc. (COSM)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 457524% more annual revenue ($337.40B vs $73.73M). COR leads profitability with a 1.0% profit margin vs -33.1%. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 6.0Value: 5.3Quality: 3.8
Piotroski: 5/9

COSM

Hold

36

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-85.6%)

Margin of Safety

-85.6%

Fair Value

$193.43

Current Price

$359.03

$165.60 premium

UndervaluedFair: $193.43Overvalued

Intrinsic value data unavailable for COSM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR4 strengths · Avg: 8.8/10
Return on EquityProfitability
94.6%10/10

Every $100 of equity generates 95 in profit

Market CapQuality
$66.67B9/10

Large-cap with strong market position

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Free Cash FlowQuality
$2.70B8/10

Generating 2.7B in free cash flow

COSM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
28.8%8/10

Revenue surging 28.8% year-over-year

Areas to Watch

COR4 concerns · Avg: 2.8/10
Price/BookValuation
18.6x4/10

Trading at 18.6x book value

Profit MarginProfitability
1.0%3/10

1.0% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Debt/EquityHealth
3.061/10

Elevated debt levels

COSM4 concerns · Avg: 3.3/10
Price/BookValuation
9.6x4/10

Trading at 9.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$20.89M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bull Case : COSM

The strongest argument for COSM centers on Revenue Growth. Revenue growth of 28.8% demonstrates continued momentum.

Bear Case : COR

The primary concerns for COR are Price/Book, Profit Margin, Operating Margin. Debt-to-equity of 3.06 is elevated, increasing financial risk. Thin 1.0% margins leave little buffer for downturns.

Bear Case : COSM

The primary concerns for COSM are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

COR profiles as a value stock while COSM is a growth play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.44 — expect wider price swings.

COSM is growing revenue faster at 28.8% — sustainability is the question.

COR generates stronger free cash flow (2.7B), providing more financial flexibility.

Bottom Line

COR scores higher overall (62/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?